Lipoprotein(a) and Heart Health: What Every Adult Should Know in 2026

Lipoprotein(a) — commonly written as Lp(a) — is one of the most important yet underrecognized cardiovascular risk factors. Unlike standard cholesterol metrics that respond readily to diet and exercise, Lp(a) is primarily determined by genetics. An estimated 20% of the global population carries elevated Lp(a) levels, and most don't know it because standard lipid panels rarely include it.

This matters because high Lp(a) is an independent risk factor for heart attack, stroke, and aortic valve disease — independent of your Lowering LDL Cholesterol Naturally, blood pressure, or other traditional markers. The good news: understanding your Lp(a) status allows you to take targeted preventive action. And with new treatments in late-stage clinical trials as of 2026, the outlook for managing elevated Lp(a) is improving rapidly.

This guide covers what Lp(a) is, why it matters, current testing recommendations, target levels, proven lifestyle strategies, and the latest treatment developments.

Key Points About Lipoprotein(a)

• Lipoprotein(a) is a genetically determined lipoprotein particle that promotes arterial plaque buildup and blood clotting — making it a dual-threat cardiovascular risk factor.

• Elevated Lp(a) affects approximately 1 in 5 people worldwide and is an independent risk factor for coronary heart disease, stroke, and aortic stenosis.

• Standard lifestyle changes have limited effect on Lp(a) because levels are 80–90% genetically determined. However, managing overall cardiovascular risk becomes more critical when Lp(a) is elevated.

• New targeted therapies — particularly the antisense oligonucleotide pelacarsen — are showing remarkable results in clinical trials, with potential approval expected in 2026–2027.

What Is Lipoprotein(a) and Why Should You Test It?

Lipoprotein(a) is a lipoprotein particle structurally similar to LDL cholesterol, but with an additional protein — apolipoprotein(a) — attached to its surface. This extra protein makes Lp(a) particularly dangerous for two reasons:

1. Accelerated atherosclerosis: Lp(a) particles are especially prone to oxidation and infiltrate arterial walls more aggressively than standard LDL particles, accelerating plaque formation.

2. Pro-thrombotic effects: Apolipoprotein(a) structurally resembles plasminogen — a protein involved in breaking down blood clots. Lp(a) essentially competes with plasminogen, impairing your body's natural clot-dissolving mechanism. This dual action (plaque buildup + impaired clot resolution) creates a compounding cardiovascular risk.

Extensive research confirms that Lp(a) is an independent risk factor for cardiovascular disease. Large-scale Mendelian randomization studies have established a causal relationship between elevated Lp(a) and coronary heart disease, aortic valve stenosis, and ischemic stroke.

Who Should Get Tested and How Often

Current guidelines from the European Atherosclerosis Society (EAS) and the National Lipid Association (NLA) recommend that every adult should have Lp(a) measured at least once in their lifetime. This baseline measurement is especially important because Lp(a) levels are largely stable throughout life — one test typically tells you your lifelong risk.

More frequent testing may be warranted for:

1. Family history: If close relatives have experienced premature heart disease (before age 55 in men or 65 in women), early heart attack, or stroke, your genetic risk is elevated.

2. Previous cardiovascular events: After a heart attack or stroke, Lp(a) testing helps determine whether elevated Lp(a) contributed and guides treatment intensity.

3. Familial hypercholesterolemia: Individuals with genetically high cholesterol should be tested for Lp(a) because the two conditions frequently co-occur and compound risk.

4. Borderline conventional risk: When standard risk calculators place you in an intermediate category, elevated Lp(a) can reclassify you to high risk — changing treatment recommendations.

Mito Health's comprehensive blood testing package includes Lp(a) alongside 66 other biomarkers — providing a complete picture of cardiovascular risk, metabolic health, and longevity markers in a single test.

Recommended Lipoprotein(a) Levels

For optimal cardiovascular health, target levels are:

• Optimal: Less than 30 nmol/L (or less than 14 mg/dL)

• Borderline: 30–50 nmol/L (14–20 mg/dL)

• Elevated: 50–125 nmol/L (20–50 mg/dL) — increased cardiovascular risk

• Very high: Above 125 nmol/L (above 50 mg/dL) — substantially increased risk requiring aggressive management of all modifiable risk factors

Important note: Because Lp(a) measurement methods vary between labs, always compare results using the same units and methodology. The preferred unit is nmol/L, which measures particle number directly rather than mass.

Lifestyle Strategies for Managing Lp(a) Risk

Unlike LDL cholesterol, Lp(a) levels are 80–90% genetically determined and respond minimally to lifestyle changes. However, when Lp(a) is elevated, optimizing every other modifiable risk factor becomes critical. Here's what works:

Diet: Heart-Protective Nutrition

While diet has limited direct effect on Lp(a) itself, a heart-protective diet reduces the overall cardiovascular risk that elevated Lp(a) amplifies:

• Omega-3 rich fish: Salmon, mackerel, and sardines 2–3 times per week reduce inflammation and triglycerides, lowering the overall burden on arteries already at risk from elevated Lp(a).

• Fiber-rich foods: Oats, legumes, and vegetables help lower LDL cholesterol — reducing the combined atherogenic particle load when Lp(a) is also elevated.

• Mediterranean pattern: The Mediterranean dietary pattern has the strongest evidence base for cardiovascular protection, with measurable benefits for endothelial function and arterial health.

• Limit saturated and trans fats: These directly raise LDL cholesterol, compounding the risk from elevated Lp(a).

Exercise: Reducing Compounding Risk

Regular physical activity doesn't significantly lower Lp(a) directly, but it reduces virtually every other cardiovascular risk factor:

• Aim for 150–300 minutes of moderate aerobic exercise per week (walking, cycling, swimming).

• Include 2–3 resistance training sessions per week for metabolic health benefits.

• Exercise improves insulin sensitivity, lowers inflammation, promotes healthy blood pressure, and supports weight management — all critical when Lp(a) is elevated.

Other Modifiable Factors

• Smoking cessation: Smoking compounds arterial damage and clotting risk — eliminating this factor is especially important with elevated Lp(a).

• Stress management: Chronic stress elevates cortisol and promotes inflammation. Regular stress-reduction practices (meditation, adequate sleep, controlled breathing) help manage overall cardiovascular risk.

• Alcohol moderation: Limit to 1 drink per day for women, 2 for men.

Pharmaceutical Treatments for Elevated Lp(a)

The treatment landscape for Lp(a) has evolved significantly. Here are the current and emerging options:

Pelacarsen (Targeted Lp(a) Reduction — In Clinical Trials)

Pelacarsen is an antisense oligonucleotide (ASO) developed by Ionis/Novartis that specifically targets Lp(a) production in the liver. It represents the most significant advance in Lp(a) management to date:

• Phase 2 trials demonstrated 80% reduction in Lp(a) levels with monthly subcutaneous injections.

• The large-scale phase 3 HORIZON trial (8,323 participants) is expected to report results in 2026, with potential regulatory approval to follow.

• If approved, pelacarsen would be the first medication specifically designed to lower Lp(a) — a milestone in cardiovascular medicine.

RNA-Based Therapies (Emerging)

Small interfering RNA (siRNA) therapies, including olpasiran and lepodisiran, are also showing strong results in clinical trials:

• Olpasiran (Amgen) achieved up to 97% Lp(a) reduction in phase 2 trials with quarterly dosing.

• Lepodisiran (Eli Lilly) demonstrated sustained Lp(a) reduction for up to 48 weeks after a single dose in phase 1 data.

• These longer-acting therapies could eventually require only 2–4 injections per year.

Niacin (Vitamin B3)

Niacin remains the most established medication for lowering Lp(a), reducing levels by 20–30% at doses of 1,000–3,000 mg per day. However, its clinical use is limited by significant side effects including flushing, itching, and potential liver inflammation. Niacin should only be used under physician supervision with regular liver function monitoring.

PCSK9 Inhibitors

PCSK9 inhibitors (evolocumab and alirocumab) are injectable monoclonal antibodies that primarily target LDL cholesterol but also reduce Lp(a) by approximately 20–30%. While not specifically designed for Lp(a), they provide an additional benefit in patients who require aggressive LDL lowering.

Supplements That May Support Heart Health

While no supplement significantly lowers Lp(a), several may help manage overall cardiovascular risk when Lp(a) is elevated:

• Omega-3 fatty acids (EPA/DHA): 2–4 grams per day reduce triglycerides and inflammation. Fish oil and krill oil are generally well-tolerated, though high doses may cause gastrointestinal discomfort.

• CoQ10 (Coenzyme Q10): 200–400 mg per day may protect LDL particles from oxidation and supports overall mitochondrial function. Particularly beneficial for those on statin therapy.

• Berberine: A natural compound that improves lipid profiles and insulin sensitivity. Some studies suggest modest LDL reduction, which helps manage total atherogenic burden.

• Vitamin K2 (MK-7): Emerging evidence suggests K2 helps direct calcium away from arterial walls — potentially beneficial when Lp(a) is promoting plaque formation.

Important: Always discuss supplements with your doctor before adding them to your routine. Supplements complement — they do not replace — lifestyle optimization and prescribed medications.

Taking Control of Your Cardiovascular Risk

Lipoprotein(a) is a powerful predictor of cardiovascular risk that most people have never heard of — and that standard health screenings often miss. Whether your Lp(a) turns out to be optimal or elevated, knowing your number empowers you to take appropriate action.

If elevated: aggressive management of all modifiable risk factors (LDL cholesterol, blood pressure, inflammation, metabolic health) becomes essential, with targeted Lp(a) therapies likely available within the next 1–2 years. If optimal: one fewer cardiovascular risk factor to worry about — valuable peace of mind.

At Mito Health, we include Lp(a) in our comprehensive biomarker panel alongside 66 other markers covering cardiovascular risk, metabolic function, hormonal balance, and longevity indicators. Our doctors provide personalized health optimization plans incorporating supplements, nutrition, exercise, and sleep strategies based on your individual results.

Sign up for our flagship package today to establish your cardiovascular baseline and take informed control of your long-term health.

Related Articles

• Strategies for Extending Your Healthspan

• Raising Ferritin Levels: Why It Matters and How to Do It Right

Resources

• Burgess et al., 2021 — Lipoprotein(a) and atherosclerotic cardiovascular disease (JAMA)

• Lipoprotein(a) — StatPearls NCBI

• Lipoprotein(a) Blood Test — MedlinePlus

• CDC — Lipoprotein(a) and Cardiovascular Disease

• Family Heart Foundation — Treating High Lp(a)

Related Biomarkers

• Lipoprotein(a) & Heart Disease: What You Should Know

• How To Improve Your Apolipoprotein B Naturally: The Key Cardiovascular Risk Marker

• LP-IR Score: A Key Biomarker for Insulin Resistance & Metabolic Health